Combination of trastuzumab, aromatase inhibitor and anti-cancer drugs obtained a good prognosis for an inoperable stage IIi B breast cancer patient with giant skin ulceration
Takeda, Y.; Tanaka, N.; Konishi, J.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(4): 629-632
2012
ISSN/ISBN: 0385-0684 PMID: 22504690 Document Number: 660935
A 68-year-old woman who had an inoperable, ER-positive, PgR-positive and HER2-positive advanced breast cancer with giant skin ulceration has been treated with the combination of trastuzumab, aromatase inhibitor and anti-cancer drugs. She was thus well-controll for over 9 years. Trastuzumab was administered more than 400 times, but no cardiac toxicity has been observed. The synergistic efficacy of the combination of trastuzumab and anti-cancer drugs was already proven, but it has recently been reported that concurrent treatment of trastuzumab and endocrine therapy improves the prognoses of triple positive breast cancer patients.